Scribe Therapeutics Inc. - Common Stock (NQ:SCTX)Price and VolumeDetailed Quote
Top NewsMore NewsPerformance
52-Week Range
49.3% below 52-week high
20.06
13.5052W Low
39.6052W High
1 Week
8.8% below 1-week high
18.001W Low
21.991W High
Scribe Therapeutics Inc. - Common Stock (SCTX) traded between $13.50 and $39.60 over the past 52 weeks and last traded at $20.06, 49.3% below its 52-week high. Over the past week it ranged between $18.00 and $21.99.
Past 12 Months
1W
+$0.94
1M
-$7.99
3M
-$1.59
6M
-$1.59
YTD
-$1.59
1Y
-$1.59
SCTX was -7.3% over the past year, -7.3% over six months, -7.3% year to date, +4.9% in the last week.
12 Months vs Market
SCTX
DIA
SPY
QQQ
IWM
Over the past 12 months SCTX returned -7.3% versus DIA (Dow) +12.1%, SPY (S&P 500) +14.5%, QQQ (Nasdaq 100) +17.4% and IWM (Russell 2000) +11.1%.
Volume & Liquidity
0.33× 3-mo avg
Today 121,699
3-mo avg 363.7K
1W
1M
3M
6M
YTD
1Y
SCTX most recently traded 121,699 shares against a 3-month average daily volume of 363.7K. More NewsRead More
Scribe Therapeutics to Participate in Upcoming Investor Conferences
September 01, 2026
Frequently Asked QuestionsIs Scribe Therapeutics Inc. - Common Stock publicly traded?
Yes, Scribe Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Scribe Therapeutics Inc. - Common Stock trade on?
Scribe Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Scribe Therapeutics Inc. - Common Stock?
The ticker symbol for Scribe Therapeutics Inc. - Common Stock is SCTX on the Nasdaq Stock Market
What is the current price of Scribe Therapeutics Inc. - Common Stock?
The current price of Scribe Therapeutics Inc. - Common Stock is 20.06
When was Scribe Therapeutics Inc. - Common Stock last traded?
The last trade of Scribe Therapeutics Inc. - Common Stock was at 10/20/26 02:34 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
|
